COLD-PCR and innovative microarray substrates for detecting and genotyping MPL exon 10 W515 substitutions

Clinical Chemistry

Volumn 58, Issue 12, 2012, Pages 1692-1702

  Brisci, Angela ^a   Damin, Francesco ^b   Pietra, Daniela ^c   Galbiati, Silvia ^a   Boggi, Sabrina ^c   Casetti, Ilaria ^c   Rumi, Elisa ^c   Chiari, Marcella ^b   Cazzola, Mario ^c   Ferrari, Maurizio ^a,d,e   Cremonesi, Laura ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^e Diagnostica e Ricerca San Raffaele   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ALLELE; ALLELIC DISCRIMINATION ASSAY; ARTICLE; ASSAY; COAMPLIFICATION AT LOWER DENATURATION TEMPERATURE POLYMERASE CHAIN REACTION; EXON; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; GRANULOCYTE; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MYELOPROLIFERATIVE LEUKEMIA VIRUS ONCOGENE; ONCOGENE; POLYMERASE CHAIN REACTION;

DNA PRIMERS; EXONS; GENOTYPE; HUMANS; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; PRIMARY MYELOFIBROSIS; THROMBOCYTHEMIA, ESSENTIAL; THROMBOPOIETIN;

MYELOPROLIFERATIVE LEUKEMIA VIRUS;

EID: 84870383332     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2012.192708     Document Type: Article

References (31)

1. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-90.
2. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-ofcare diagnostic algorithms. Leukemia 2008;22:14-22.
3. Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 2008;22:1299-307.
4. Tefferi A, Lasho TL, Schwager SM, Strand JS, Elliott M, Mesa R, et al. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer 2006;106:631-5.
5. Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 2010;24:1574-9.
6. Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V, et al. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 2007;21:1952-9.
7. Barosi G, Bergamaschi G, Marchetti M, Vannucchi AM, Guglielmelli P, Antonioli E, et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 2007;110:4030-6.
8. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006;3:e270.
9. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006;108:3472-6.
10. Guglielmelli P, Pancrazzi A, Bergamaschi G, Rosti V, Villani L, Antonioli E, et al. Anaemia characterises patients with myelofibrosis harbouring MPL mutation. Br J Haematol 2007;137:244-7.
11. Williams DM, Kim AH, Rogers O, Spivak JL, Moliterno AR. Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis. Exp Hematol 2007;35:1641-6.
12. Beer PA, Campbell PJ, Scott LM, Bench AJ, Erber WN, Bareford D, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 2008;112:141-9.
13. Vannucchi AM, Antonioli E, Guglielmelli P, Pancrazzi A, Guerini V, Barosi G, et al. Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood 2008;112:844-7.
14. Chaligne R, Tonetti C, Besancenot R, Roy L, Marty C, Mossuz P, et al. New mutations of MPL in primitive myelofibrosis: Only the MPL W515 mutations promote a G1/S-phase transition. Leukemia 2008;22:1557-66.
15. Schnittger S, Bacher U, Haferlach C, Beelen D, Bojko P, Burkle D, et al. Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis. Haematologica 2009;94:141-4.
16. Boyd EM, Bench AJ, Goday-Fernandez A, Anand S, Vaghela KJ, Beer P, et al. Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis. Br J Haematol 2010;149:250-7.
17. Li J, Wang L, Mamon H, Kulke MH, Berbeco R, Makrigiorgos GM. Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. Nat Med 2008;14:579-84.
18. Li J, Makrigiorgos GM. COLD-PCR: a new platform for highly improved mutation detection in cancer and genetic testing. Biochem Soc Trans 2009;37:427-32.
19. Galbiati S, Brisci A, Lalatta F, Seia M, Makrigiorgos GM, Ferrari M, et al. Full COLD-PCR protocol for noninvasive prenatal diagnosis of genetic diseases. Clin Chem 2011;57:136-8.
20. Pietra D, Brisci A, Rumi E, Boggi S, Elena C, Pietrelli A, et al. Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms. Haematologica 2011;96:607-11.
21. Galbiati S, Damin F, Di Carlo G, Ferrari M, Cremonesi L, Chiari M. Development of new substrates for high-sensitive genotyping of minority mutated alleles. Electrophoresis 2008;29:4714-22.
22. Bruno F, Damin F, Causarano V, Galbiati S, Di Carlo G, Seia M, et al. High-sensitive microarray substrates specifically designed to improve sensitivity for the identification of fetal paternally inherited sequences in maternal plasma. Clin Chem Lab Med 2009;47:818-23.
23. Mesa RA, Verstovsek S, Cervantes F, Barosi G, Reilly JT, Dupriez B, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Leuk Res 2007;31:737-40.
24. Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008;22:437-8.
25. Malcovati L, Della Porta MG, Pietra D, Boveri E, Pellagatti A, Galli A, et al. Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Blood 2009;114:3538-45.
26. Cooper KL, Goering RV. Development of a universal probe for electronic microarray and its application in characterization of the Staphylococcus aureus polC gene. J Mol Diagn 2003;5:28-33.
27. Pirri G, Damin F, Chiari M, Bontempi E, Depero LE. Characterization of a polymeric adsorbed coating for DNA microarray glass slides. Anal Chem 2004;76:1352-8.
28. Stenirri S, Fermo I, Battistella S, Galbiati S, Soriani N, Paroni R, et al. Denaturing HPLC profiling of the ABCA4 gene for reliable detection of allelic variations. Clin Chem 2004;50:1336-43.
29. Pietra D, Li S, Brisci A, Passamonti F, Rumi E, Theocharides A, et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 2008;111:1686-9.
30. Ma W, Zhang X, Wang X, Zhang Z, Yeh CH, Uyeji J, et al. MPL mutation profile in JAK2 mutationnegative patients with myeloproliferative disorders. Diagn Mol Pathol 2011;20:34-9.
31. Milbury CA, Li J, Liu P, Makrigiorgos GM. COLDPCR: improving the sensitivity of molecular diagnostics assays. Expert Rev Mol Diagn 2011;11:159-69.